Oorspronkelijke tekst
Deze vertaling beoordelen
Je feedback wordt gebruikt om Google Translate te verbeteren
Home
Suven Life Sciences Limited
Press Release Jan 08 2025
Business
Jan 8 2025
4 min read

Press Release Jan 08 2025

Suven Life Sciences Limited has informed the Exchange regarding a press release dated January 08, 2025, titled "Suven Life Sciences Announces First Subjects Dosed in Phase-1 Clinical Trial of SUVN-I6107, a True Muscarinic M1 Positive Allosteric Modulator (M1 PAM) for the Treatment of Cognitive Disorders".

View Attachment